0.178
price down icon0.22%   -0.0004
after-market アフターアワーズ: .18 0.002 +1.12%
loading
前日終値:
$0.1784
開ける:
$0.18
24時間の取引高:
10.85M
Relative Volume:
0.51
時価総額:
$87.01M
収益:
$55.54M
当期純損益:
$-180.40M
株価収益率:
-0.226
EPS:
-0.7877
ネットキャッシュフロー:
$-170.32M
1週間 パフォーマンス:
+5.01%
1か月 パフォーマンス:
+0.28%
6か月 パフォーマンス:
-92.12%
1年 パフォーマンス:
-89.77%
1日の値動き範囲:
Value
$0.1729
$0.1816
1週間の範囲:
Value
$0.16
$0.187
52週間の値動き範囲:
Value
$0.1138
$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name
名前
Gossamer Bio Inc
Name
セクター
Healthcare (1077)
Name
電話
(858) 684-1300
Name
住所
3115 MERRYFIELD ROW, SAN DIEGO, CA
Name
職員
162
Name
Twitter
@GossamerBio
Name
次回の収益日
2026-08-04
Name
最新のSEC提出書
Name
GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ARGX, RVMD, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GOSS icon
GOSS
Gossamer Bio Inc
0.178 97.48M 55.54M -180.40M -170.32M -0.7877
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
496.07 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
784.36 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
865.04 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
205.15 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
348.27 33.81B 5.76B 514.49M 1.10B 4.4813

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2026-02-24 ダウングレード Barclays Overweight → Equal Weight
2026-02-24 ダウングレード Leerink Partners Outperform → Market Perform
2026-02-24 ダウングレード Wedbush Outperform → Neutral
2026-01-28 開始されました Barclays Overweight
2025-09-10 アップグレード UBS Neutral → Buy
2025-07-14 開始されました Scotiabank Sector Outperform
2024-06-25 開始されました Oppenheimer Outperform
2024-04-05 再開されました Wedbush Outperform
2023-07-27 ダウングレード UBS Buy → Neutral
2023-03-07 ダウングレード Raymond James Outperform → Mkt Perform
2023-03-01 開始されました Guggenheim Neutral
2022-12-07 ダウングレード Barclays Overweight → Equal Weight
2022-12-07 ダウングレード JP Morgan Neutral → Underweight
2022-12-07 ダウングレード SMBC Nikko Outperform → Neutral
2022-10-20 開始されました Goldman Buy
2022-09-21 開始されました JP Morgan Neutral
2022-09-19 開始されました Wedbush Outperform
2022-04-18 開始されました Raymond James Outperform
2022-04-06 開始されました UBS Buy
2022-01-10 アップグレード SMBC Nikko Neutral → Outperform
2021-11-09 再開されました Cantor Fitzgerald Overweight
2021-09-21 再開されました Piper Sandler Overweight
2020-06-29 開始されました H.C. Wainwright Buy
2020-04-22 開始されました Piper Sandler Overweight
2020-02-27 開始されました Barclays Overweight
2019-12-03 再開されました BofA/Merrill Buy
2019-10-30 開始されました Berenberg Buy
2019-03-05 開始されました Barclays Overweight
2019-03-05 開始されました BofA/Merrill Buy
2019-03-05 開始されました Evercore ISI Outperform
2019-03-05 開始されました SVB Leerink Outperform
すべてを表示

Gossamer Bio Inc (GOSS) 最新ニュース

pulisher
Jul 28, 2026

$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo

Jul 28, 2026
pulisher
Jul 28, 2026

GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus

Jul 28, 2026
pulisher
Jul 28, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jul 28, 2026
pulisher
Jul 28, 2026

Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com

Jul 28, 2026
pulisher
Jul 28, 2026

Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com UK

Jul 28, 2026
pulisher
Jul 28, 2026

Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²

Jul 28, 2026
pulisher
Jul 28, 2026

Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Moomoo

Jul 28, 2026
pulisher
Jul 27, 2026

Leerink Partners Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Cuts Target Price to $1 - Moomoo

Jul 27, 2026
pulisher
Jul 27, 2026

GOSS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver Quantitative

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingView

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom - TechStock²

Jul 27, 2026
pulisher
Jul 27, 2026

GOSS: Key Regulatory and Corporate Developments Announced - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Benzinga

Jul 27, 2026
pulisher
Jul 27, 2026

GOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocus

Jul 27, 2026
pulisher
Jul 27, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio stock surges 25% on FDA regulatory update By Investing.com - Investing.com UK

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio stock surges 25% on FDA regulatory update - Investing.com

Jul 27, 2026
pulisher
Jul 27, 2026

Why is Gossamer Bio stock surging today? By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio plans September NDA submission for seralutinib By Investing.com - Investing.com Nigeria

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Inc (GOSS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Inc (GOSS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

$Gossamer Bio (GOSS.US)$ mood today - Moomoo

Jul 27, 2026
pulisher
Jul 27, 2026

Gossamer Bio Inc (GOSS) Balance Sheet - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

$Gossamer Bio (GOSS.US)$ - Moomoo

Jul 26, 2026
pulisher
Jul 26, 2026

GOSS|Gossamer Bio Inc|Price:0.147|Chg%:+0.011 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Gossamer Bio Inc (GOSS) Income Statement - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Gossamer Bio, Inc. Revenue Breakdown – NASDAQ:GOSS - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006 - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

Form 13D/A Gossamer Bio For: 24 July By Investing.com - Investing.com Nigeria

Jul 24, 2026
pulisher
Jul 24, 2026

Gossamer Bio Inc (GOSS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 21, 2026

ETFs Investing in Gossamer Bio, Inc. Stocks - TradingView

Jul 21, 2026
pulisher
Jul 21, 2026

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill

Jul 21, 2026
pulisher
Jul 20, 2026

Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook - Ad-hoc-news.de

Jul 20, 2026
pulisher
Jul 17, 2026

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits

Jul 17, 2026
pulisher
Jul 16, 2026

Gossamer Bio(GOSS) Stock Options Chain | Quotes & News - Moomoo

Jul 16, 2026
pulisher
Jul 16, 2026

Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 16, 2026
pulisher
Jul 15, 2026

Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Remains KeyPost-Announcement Reaction - dars.gov.et

Jul 15, 2026
pulisher
Jul 15, 2026

CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - AOL.com

Jul 15, 2026
pulisher
Jul 15, 2026

Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan

Jul 15, 2026
pulisher
Jul 13, 2026

Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB - TradingView

Jul 13, 2026
pulisher
Jul 11, 2026

Gossamer Bio (GOSS) Proxy filing Summary - Quartr

Jul 11, 2026
pulisher
Jul 10, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 10, 2026
pulisher
Jul 09, 2026

Gossamer Bio (GOSS) Income Statement & Earnings - Moomoo

Jul 09, 2026

Gossamer Bio Inc (GOSS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$120.56
price up icon 1.84%
$56.77
price down icon 0.86%
$36.34
price up icon 3.47%
$131.10
price down icon 1.09%
$219.20
price up icon 1.43%
ONC ONC
$348.27
price up icon 5.60%
大文字化:     |  ボリューム (24 時間):